Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
BICO Group AB Class B ( (SE:BICO) ) just unveiled an update.
BICO’s subsidiary, Biosero, has signed a master service agreement with a global pharmaceutical company to develop integrated lab automation solutions valued at 15.2 million USD. This project, which will run from September 2025 to the end of 2026, aims to enhance the customer’s drug development process using Biosero’s Green Button Go software. The agreement is expected to strengthen BICO’s market position by showcasing their expertise in lab automation and fostering long-term relationships with key industry players.
The most recent analyst rating on (SE:BICO) stock is a Hold with a SEK36.00 price target. To see the full list of analyst forecasts on BICO Group AB Class B stock, see the SE:BICO Stock Forecast page.
More about BICO Group AB Class B
BICO is a lab automation partner and provider of selected workflows to the pharma and biotech industries. With over 48,000 instruments installed in more than 65 countries, BICO’s products, software, and solutions are present in over 3,500 laboratories, including those of the world’s top 20 pharmaceutical companies. BICO operates through two business areas: Lab Automation and Life Science Solutions, and is listed on Mid-Cap, Nasdaq Stockholm.
Average Trading Volume: 257,799
Technical Sentiment Signal: Sell
Current Market Cap: SEK1.62B
Find detailed analytics on BICO stock on TipRanks’ Stock Analysis page.